We are excited to share that Strateos’ SVP of Strategy & Operations, Daniel Sipes, will be delivering a presentation entitled Accelerating Medicinal Chemistry Cycle Times Through Cloud-Accessible Smart Automated Labs at the upcoming 2022 Society for Laboratory Automation and Screening Conference & Exhibition between February 5-9th.
SLAS 2022 is set to be an exciting conference where scientists can come together to learn about the innovative technologies transforming the way life sciences research is executed. The conference will be held in Boston, MA, and will feature thought-provoking presentations and an exhibition showcasing laboratory automation solutions and services.
A DIRECT ROUTE TO SMART LABS – REIMAGINING AND REDEFINING LABS AS SMART DATA CENTERS
Strateos’ SVP of Strategy and Operations, Daniel Sipes, will be giving a talk during SLAS 2022 on February 7th at 4:30pm EST, discussing the challenges associated with the design, make, test and analyze (DMTA) cycle in small molecule drug discovery workflows where medicinal chemistry plays a key role. Progress from target ID through to IND submission in conventional workflows can take upwards of 6+ years, where success hinges on iterative cycles of DMTA. However, fractured workflows, operational bottlenecks and non-standardized analog data capture has resulted in high cost and slow cycle times that cannot support the urgent and growing demand for new drug discoveries.
Strateos’ multi-facility laboratory located in San Diego and Menlo Park, California, which collectively span 14K sq. ft. with >200 instruments and 25 automation modules enables more rapid optimization of reaction conditions for the synthesis of chemical compounds and supports a range of the most common single-step reactions used in discovery synthetic MedChem. Additionally, API integration with other digital tools, such as third party ELNs and LIMS, enable scientists to design, control, and collaborate on scientific workflows. After purification and structural verification, the target compounds can be assayed in the same smart lab facilities for functional testing, such as inhibition assays, accelerating the DMTA cycle. Automation of key DMTA steps in lead discovery and optimization improves process efficiencies and reduces cycle times, as well as liberating medicinal chemists to focus on more critical aspects of the workflow and/or work on multiple projects simultaneously.
Daniel will discuss key learnings and results of automating the DMTA cycle after over a year operating in production mode, including the reduction of researchers’ hands-on time by 90%, ability to screen 1M+ molecules in as little as two weeks to identify lead scaffolds, and automated reproducible synthesis of compounds followed by downstream cell-based and biochemical assays such as cAMP, kinase, and label-free mass spec assays in as little as 3-5 days.
Additionally, Strateos' Senior Director of R&D Strategy, Daniel Rines, Ph.D., will be participating in a panel discussion during SLAS2022 February 7th 4:30-6:00pm EST alongside other thought leaders to discuss artificial intelligence in labs now and in the future.
We hope you can join us for these presentations and more at SLAS 2022! For general conference information and/or to register, please click the link below: https://www.slas.org/events-calendar/slas2022-international-conference-and-exhibition/
To learn more about our cloud-accessible smart lab platform: https://strateos.com/strateos-control-our-lab/